Table IV.
Effect of Formulation (A) and Frequency of Applications (B) of Oxyresveratrol Microemulsion in Cutaneous HSV-1 Infection in Mice
| Treatmenta | Mean timeb (days, mean ± SD) | % Mortalityc | |||
|---|---|---|---|---|---|
| Score 2 | Score 4 | Score 6 | Survival | ||
| A. Effect of formulation | |||||
| Untreated control | 5.65 ± 0.29 | 6.21 ± 0.50 | 7.02 ± 0.58 | 8.03 ± 0.42 | 100 |
| ORME 10%, ×3 | 6.88 ± 0.62d | 7.17 ± 0.63d | >7.80 ± 0.98 | >8.58 ± 0.78 | 88.89 |
| ORME 20%, ×3 | >7.96 ± 2.06d | >8.36 ± 1.61d | >8.95 ± 0.99d | >9.14 ± 0.81d | 55.56e |
| OR in Vaseline 30%, ×3 | >6.69 ± 1.38d | >6.79 ± 0.59d | >8.10 ± 0.95d | >8.87 ± 1.00d | 33.33e |
| ACV 5%, ×3 | >10d | >10d | >10d | >10d | 0e |
| B. Effect of frequency of applications | |||||
| Untreated control | 5.37 ± 0.31 | 6.49 ± 0.49 | 7.49 ± 0.30 | 8.03 ± 0.89 | 100 |
| ORME 10%, ×3 | 6.30 ± 0.82d | 6.78 ± 0.39 | >7.78 ± 0.93 | >8.10 ± 0.86 | 62.5e |
| ORME 10%, ×4 | >7.48 ± 1.59d | >7.73 ± 1.43d | >8.58 ± 1.19d | >8.83 ± 0.98 | 62.5e |
| ORME 10%, ×5 | >8.10 ± 1.60d | >8.18 ± 1.38d | >8.85 ± 1.16d | >9.15 ± 0.97d | 50e |
OR oxyresveratrol, ORME oxyresveratrol-loaded ME, ACV acyclovir, SD standard deviation
aORME was topically applied five times daily for 10 days after HSV-1 infection
bMean time at which score 2, 4, and 6 or survival was observed after infection, determined from nine to ten mice in each group (the mean time with symbol > referred to a group of mice that had mice showing score 0 at day 10)
cPercentage of mortality of mice tested, observed at day 10 after HSV-1 infection
dMean time was significantly prolonged (p < 0.05 vs. untreated control)
eMortality was significantly reduced (p < 0.05 vs. untreated control)